On a warm June morning in Nairobi, health officials from Kenya, Malawi, and Zambia gathered with over 80 global experts, TB survivors, and civil society leaders in a quiet but determined push to prepare for a future where tuberculosis—a disease that still claims over 400,000 lives annually in Africa—could be dramatically curbed by a new generation of vaccines. Hosted by the World Health Organization from June 3–5, the workshop marked a pivotal moment in Africa’s fight against TB, bringing together immunization and TB specialists to lay the groundwork for the potential rollout of novel vaccines for adults and adolescents, currently in late-stage clinical trials. With a vaccine potentially licensable as early as 2029, the urgency was palpable: every delay risks millions of preventable cases and deaths.
Tuberculosis remains one of the world’s deadliest infectious diseases, and in Africa, it hits hardest. Each year, 2.5 million fall ill and more than 400,000 lose their lives. But the promise of a new vaccine—one with 50% efficacy—could change everything. WHO estimates that over 25 years, such a vaccine could avert up to 76 million new TB cases, prevent 8.5 million deaths, eliminate 42 million courses of antibiotic treatment, and save $6.5 billion in household costs, particularly for the poorest and most vulnerable. Kenya, already participating in late-stage clinical trials, is poised to be one of the first countries in the region to implement the vaccine, with Malawi and Zambia following close behind.
The Nairobi workshop distilled lessons from recent vaccine rollouts—like those for malaria and COVID-19—into actionable strategies. Participants emphasized the need for country-specific roadmaps, multi-functional technical working groups, and early integration of TB vaccines into national immunization and TB control programs. Civil society, faith-based organizations, and community leaders were highlighted as essential partners in building public trust and ensuring equitable access. Countries also recognized the need for implementation research and modeling studies to inform regulatory decisions, with funding support likely required to move forward.
Political will and sustainable financing emerged as critical pillars. Delegates agreed that engaging parliamentary bodies and high-level decision-makers is essential to secure long-term domestic investment and create an enabling policy environment. The workshop built on earlier preparedness efforts in Indonesia and South Africa, both of which shared valuable insights from their own trial participation and planning processes.
As the meeting closed, a shared vision took shape: a coordinated, Africa-led effort to ensure that when the first new TB vaccine is approved, countries won’t just be ready—they’ll be ahead of the curve. The road ahead is complex, but the momentum is real. With trials underway and plans forming, the dream of ending TB is no longer a distant hope, but a tangible goal within reach.